Illimis Therapeutics
Illimis Therapeutics specializes in developing novel biologics based on its proprietary chimeric fusion protein platform. The platform aims to address neurodegenerative diseases such as Alzheimer's by utilizing TAM receptor-mediated phagocytosis, which reduces neuroinflammation
Currently, there are no issues on this topic.
Find more companies like Illimis Therapeutics
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
By using this site, you agree to our Terms of Service.